Hanna K. Laitinen

Hanna K. Laitinen

Auto-generated profile, based on publicly available information

Hanna K. Laitinen

Helsinki University Hospital 3 iCAN Digital Precision Cancer Medicine Flagship , Helsinki, Finland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Science Advances
Verified
Journal Article
Open access
BABassel Alsaed
Bassel Alsaed
JSJohannes Smolander
Johannes Smolander
HLHanna Laitinen
Hanna Laitinen
LLLinh Lin
Linh Lin
NBNina Bobik
Nina Bobik
HHHeidi M. Haikala
Heidi M. Haikala
Despite immunotherapy’s promise in cancer treatment, patient responses vary substantially because of the individual nature of the immune system and the lack of reliable biomarkers. To address this issue, we developed a precision ex vivo platform that integrates patient-specific tumor and immune cells to study the mechanisms of antitumor immune response, predict immunotherapy outcomes, and identify effective treatments. This platform revealed unique single-cell immune response mechanisms and sensitivities to standard-of-care immunotherapies. Furthermore, we were able to identify a synergistic combination of anti–programmed cell death protein 1 (anti–PD-1) together with a Casitas B lineage lymphoma-b inhibitor that overcame anti–PD-1 resistance in selected patient samples. Activation of the interferon-γ–stimulated cytokines predicted combination efficacy, while immunosuppressive cytokines were associated with poor response. Our findings underscore the platform’s potential in tailoring immunotherapies and advancing drug development, offering avenues for personalized cancer treatment.

1 February 2026 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
NSNeja Sirc
Neja Sirc
JSJohannes Smolander
Johannes Smolander
AKAnita N. Kumari
Anita N. Kumari
JLJianyin Liu
Jianyin Liu
MLMoon Hee Lee
Moon Hee Lee
KPKarita Peltonen
Karita Peltonen
Immune cells in the tumor microenvironment (TME) are attractive therapeutic targets; however, their responses to immunotherapy and targeted therapy remain incompletely understood. We developed a patient-derived ex vivo system to profile baseline immune characteristics and model treatment-induced activation at the single-cell level. The model was utilized to study T cell responses to PD-1 blockade and VEGFR inhibition (VEGFRi) in patients with renal cell carcinoma (RCC). The baseline RCC TME was highly infiltrated by T cells, characterized by diverse cytotoxic, memory, exhausted, or regulatory phenotypes. T cells were activated by direct CD3/CD28/CD2 stimulation, upregulating the IFN-γ, TNF, and IL2 signaling pathways. However, activation capacity varied noticeably depending on the baseline phenotype. PD-1 blockade induced modest T cell activation, whereas VEGFRi downregulated several immune markers, including signaling pathways and immune activation-related cytokines. Our study reveals the suppressive features of the RCC TME and the challenge of fully overcoming it with PD-1 blockade and VEGFRi. Significance: We developed a patient-derived ex vivo model to study immune cell therapy responses within the TME of RCC. Immune activation toward PD-1 blockade and VEGFRi was attenuated and depended on the immune cell state.

26 February 2026
Verified
Other
Open access
NSNeja Sirc
Neja Sirc
JSJohannes Smolander
Johannes Smolander
AKAnita N. Kumari
Anita N. Kumari
JLJianyin Liu
Jianyin Liu
MLMoon Hee Lee
Moon Hee Lee
KPKarita Peltonen
Karita Peltonen
Differentially expressed genes (DEGs) in pseudobulked treatment vs control in CD8+ cells

26 February 2026
Verified
Other
Open access
NSNeja Sirc
Neja Sirc
JSJohannes Smolander
Johannes Smolander
AKAnita N. Kumari
Anita N. Kumari
JLJianyin Liu
Jianyin Liu
MLMoon Hee Lee
Moon Hee Lee
KPKarita Peltonen
Karita Peltonen
Cell-cell interaction changes in anti-CD3/CD28/CD2 vs Control according to Liana+

26 February 2026
Verified
Other
Open access
NSNeja Sirc
Neja Sirc
JSJohannes Smolander
Johannes Smolander
AKAnita N. Kumari
Anita N. Kumari
JLJianyin Liu
Jianyin Liu
MLMoon Hee Lee
Moon Hee Lee
KPKarita Peltonen
Karita Peltonen
Cell-cell interaction changes in anti-PD1 + VEGFRi vs Control according to Liana+

26 February 2026
Verified
Other
Open access
NSNeja Sirc
Neja Sirc
JSJohannes Smolander
Johannes Smolander
AKAnita N. Kumari
Anita N. Kumari
JLJianyin Liu
Jianyin Liu
MLMoon Hee Lee
Moon Hee Lee
KPKarita Peltonen
Karita Peltonen
Enriched pathways in differentially expressed genes (DEGs) in treatment vs control in CD4+ cells according to Metascape